STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that ...
The Clarity AD study included an optional Tau PET substudy and used the tau PET probe MK6240** to identify patients with a low accumulation of tau in the brain, which represents the earlier stage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback